Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size

Celine Berthon; Morgane Nudel; Eileen M Boyle; Laure Goursaud; Thomas Boyer; Alice Marceau; Bruno Quesnel

doi:10.1016/j.lrr.2020.100202

Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size

Leuk Res Rep. 2020 Apr 23:13:100202. doi: 10.1016/j.lrr.2020.100202. eCollection 2020.

Authors

Celine Berthon^{1

2}, Morgane Nudel¹, Eileen M Boyle¹, Laure Goursaud¹, Thomas Boyer^{2

3}, Alice Marceau^{2

3}, Bruno Quesnel^{1

2

3

4}

Affiliations

¹ CHU Lille, Service des Maladies du Sang, F-59000 Lille, FRANCE.
² CNRS, Inserm, UMR9020 - UMR-S 1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, FRANCE.
³ CHU Lille, Laboratory of Hematology, F-59000 Lille, FRANCE.
⁴ Univ. Lille, F-59000 Lille, FRANCE.

Abstract

Synchronous diagnosis of acute myeloid leukemia (AML) and symptomatic multiple myeloma (MM) is a rare situation that poses serious therapeutic difficulties. We report the case of a 68-year-old male which evolved simultaneously to symptomatic MM and AML. Both diseases first responded to treatment for 40 months after 7+3 induction and maintenance therapy of azacytidine + lenalidomide. MM relapsed first and was treated with azacytidine + daratumumab, which led an additional 15 months of progression-free survival. Little myeloid clonal size reduction over time was seen. This case shows that AML and MM can be effectively treated simultaneously using appropriate combinations.

Keywords: AML; Azacytidine; CMML; Clonality; Daratumumab; Lenalidomide; Myeloma.

Publication types

Case Reports